Vir Biotechnology Inc

VIR

NASDAQ. Currency in USD

25.42 -0.38 ( -1.47% )

Real time prices: December 09

Market Cap.
3.38B
Beta (5Y monthly)
-0.01
Price/Earnings
3.13
EPS (TTM)
8.49
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
564,022
1y Target Est.
49.50
Day's Range
25.34
-
25.92
52 Week's Range
18.05
-
58.00

Historical Summary

Performance
EPS growth
Share Buybacks

About Vir Biotechnology Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.vir.bio
Exchange
NASDAQ (XNAS)
Shares Outstanding
130.88M
Employees
444
Address
499 Illinois Street, San Francisco, CA, United States, 94158
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Latest news

Is Biogen (BIIB) Stock Undervalued Right Now?
Is Biogen (BIIB) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings...
By Zacks Investment Research - 1 day ago

2 Fast-Growing Healthcare Stocks to Buy and Hold
2 Fast-Growing Healthcare Stocks to Buy and Hold

The innovative companies have made great gains in a short period of time.
By The Motley Fool - 1 week ago

BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts

Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2%...
By Benzinga - 1 week ago

Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 71%: Here's is How to Trade
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 71%: Here's is How to Trade

The consensus price target hints at a 70.9% upside potential for Vir Biotechnology, Inc. (VIR)....
By Zacks Investment Research - 2 weeks ago

Should Value Investors Buy Vir Biotechnology (VIR) Stock?
Should Value Investors Buy Vir Biotechnology (VIR) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings...
By Zacks Investment Research - 2 weeks ago

5 Winning Stocks Backed by the Overlooked Rising P/E Trick
5 Winning Stocks Backed by the Overlooked Rising P/E Trick

Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream...
By Zacks Investment Research - 2 weeks ago

Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?

Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for...
By Zacks Investment Research - 3 weeks ago